Status:
COMPLETED
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
Lead Sponsor:
Pfizer
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will b...
Eligibility Criteria
Inclusion
- advanced measurable Non-Small Cell Lung Cancer (NSCLC);
- progressed after 1-2 prior chemotherapy;
- Eastern Cooperative Oncology Group (ECOG) 0-2;
- tissue available for future KRAS/ EGFR testing
Exclusion
- prior Epidermal Growth Factor Receptor (EGFR) targeted therapy;
- active or untreated Central Nervous System (CNS) metastases;
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT00769067
Start Date
November 1 2008
End Date
August 1 2014
Last Update
October 7 2015
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwest Alabama Cancer Center
Muscle Shoals, Alabama, United States, 35661
2
Agajanian Institute of Oncology and Hematology
Montebello, California, United States, 90640
3
Bridgeport Hospital
Bridgeport, Connecticut, United States, 06610
4
Wittingham Cancer Center @ Norwalk Hospital
Norwalk, Connecticut, United States, 06856